XWAR
SNT
Market cap707mUSD
Oct 30, Last price
327.00PLN
1D
-1.74%
1Q
-9.67%
Jan 2017
1,970.93%
IPO
3,922.14%
Name
Synektik SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Synektik Spólka Akcyjna, founded in 2001 and headquartered in Warsaw, Poland, operates as a comprehensive provider of products, services, and information technology solutions within the Polish market. The company focuses its offerings on the fields of surgery, diagnostic imaging, and nuclear medicine. Its core business activities include the distribution of medical equipment utilized in diagnostics, therapy, and nuclear medicine, alongside the creation of specialized IT solutions for radiology. Synektik also manufactures and supplies radiopharmaceutical products crucial for cancer diagnostics. In addition to these, it maintains a research laboratory dedicated to advancing diagnostic imaging systems and runs a service center for medical apparatus. The company further extends its services to include maintenance for medical equipment and the execution of essential acceptance and specialist tests.
Related entities
Subsidiaries
SYNEKTIK CZECH REPUBLIC, S.R.O.
Key people
Cezary Kozanecki
Chairman of the Management Board, Chief Executive Officer · since 2011
Dariusz Korecki
Vice Chairman of the Management Board · since 2017
Katarzyna Debowska
Chief Accounting Officer
Artur Ostrowski
Member of the Management Board · since 2017
Tomasz Wrobel
Member of the Management Board · since 2025
Secretary of the Supervisory Board · since 2018
Chairman of the Supervisory Board · since 2018
Vice Chairman of the Supervisory Board · since 2018
Michal Dobak
Member of the Supervisory Board · since 2025
Andrzej Jacaszek
Member of the Supervisory Board · since 2024
Headquarters & legal address
WARSZAWA JÓZEFA PIUSA DZIEKOŃSKIEGO 3
WARSZAWA, 14 00-728
PL
WARSZAWA, 14 00-728
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||